Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Edesa Biotech (EDSA) EBITDA (2016 - 2022)

Edesa Biotech's EBITDA history spans 10 years, with the latest figure at -$2.9 million for Q3 2022.

  • For Q3 2022, EBITDA rose 25.04% year-over-year to -$2.9 million; the TTM value through Sep 2022 reached -$17.6 million, down 32.4%, while the annual FY2025 figure was -$7.1 million, 14.69% down from the prior year.
  • EBITDA for Q3 2022 was -$2.9 million at Edesa Biotech, up from -$5.8 million in the prior quarter.
  • Across five years, EBITDA topped out at -$347089.0 in Q4 2018 and bottomed at -$5.8 million in Q2 2022.
  • The 5-year median for EBITDA is -$1.7 million (2020), against an average of -$2.6 million.
  • The largest annual shift saw EBITDA soared 75.03% in 2018 before it plummeted 232.82% in 2020.
  • A 5-year view of EBITDA shows it stood at -$347089.0 in 2018, then tumbled by 210.07% to -$1.1 million in 2019, then tumbled by 186.26% to -$3.1 million in 2020, then tumbled by 41.1% to -$4.3 million in 2021, then soared by 33.25% to -$2.9 million in 2022.
  • Per Business Quant, the three most recent readings for EDSA's EBITDA are -$2.9 million (Q3 2022), -$5.8 million (Q2 2022), and -$4.6 million (Q1 2022).